Scandinavian Intensive Care Unit (ICU) Glutamine Study

• Status: Terminated
• Trial end date: 2009-08-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a prospective double-blinded placebo-controlled block randomized study in intensive care patients comparing intravenous glutamine supplementation to placebo. The hypothesis is an improvement of clinical outcome. The primary endpoint is a reduction in the Sequential Organ Failure Assessment (SOFA) score on day 7 of treatment.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Scandinavian Critical Care Trials Group

Criteria

Inclusion Criteria:

• admission to the ICU

• decision to give the patient full nutrition

• APACHE II score > 10 at admission

• age 18-85 years

Exclusion Criteria:

• readmission to the ICU after a previous ICU-stay in which the patient has been included into the study

• subjects with any condition which in the opinion of the attending physician makes the subject unsuitable for inclusion

• no informed consent